Welcome to our dedicated page for Cogent Biosciences news (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.
Cogent Biosciences develops precision therapies for genetically defined diseases, with recurring updates centered on bezuclastinib and KIT-driven disorders including Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST). News commonly covers bezuclastinib clinical data from the SUMMIT and PEAK programs, U.S. FDA New Drug Application activity, medical-meeting presentations and related business updates.
Company announcements also describe preclinical oncology programs such as CGT1263, a KRAS inhibitor candidate, and CGT4255, a brain-penetrant ErbB2/HER2 inhibitor candidate. Financial-result releases and capital updates address cash resources, at-the-market equity activity and Nasdaq inducement equity awards.
Cogent Biosciences (COGT) reported third-quarter 2020 financial results, highlighting a net loss of $50 million, or $5.07 per share, compared to a loss of $11.9 million in Q3 2019. Collaboration revenue decreased to $0.3 million, down from $1.0 million year-over-year. R&D expenses were reduced to $5 million, while G&A expenses increased to $5.6 million. The company completed the acquisition of Kiq LLC and raised $104.4 million through a Series A preferred stock placement. Following a 1-for-4 reverse stock split on November 6, 2020, COGT's common stock began trading on a split-adjusted basis.
Cogent Biosciences (COGT) announced that CEO Andrew Robbins will present a corporate overview at the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The presentation will focus on Cogent's precision therapies for genetically defined diseases, including the advanced clinical program PLX9486, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, associated with systemic mastocytosis and gastrointestinal stromal tumors. A recording of the presentation will be available on the company's investor relations website.
Cogent Biosciences, Inc. (NASDAQ: COGT) announced the appointment of Andrew Robbins as President and CEO, succeeding Chuck Wilson who founded the company in 2014. Robbins brings over 20 years of experience in oncology and hematology, including his previous role as COO at Array Biopharma. The board approved an inducement award for Robbins comprising options to purchase 7,442,421 shares at the recent closing price. Cogent aims to advance its lead asset, PLX9486, in treating systemic mastocytosis and GIST.